ADRONALINE

The annual accounts of ADRONALINE for financial year 2025 show a net loss of 174% of total assets and of 91% of the equity at the start of that year. The 2025 annual accounts show equity of €953 and a net result of -€9,906. Equity is shrinking by about 37% per year and would, assuming unchanged policy, indicatively turn negative around financial year 2026. Its solvency ranks better than 20% of 10,757 sector peers (NACE 70, financial year 2025). The company has been active since 2018 and the Belgian Official Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 0.2% (very low).